To the Editor,Programmed death-1 (PD-1) checkpoint inhibitors have shown promising results for the treatment of various tumor types, including relapsed and refractory Hodgkin’s lymphoma (HL) [1,2]....
No takes yet. Share an insight, caveat, or question.
Lee et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: